Status: Recruiting
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.
Participants needed: 10
Trial details
Phase: Phase 1Age: 8-18Biological sex: MaleType: InterventionalSponsor: Larry W. MarkhamUpdated: Jul 1, 2026Locations: 1
Eligibility criteria
Clinical phenotype of DMD confirmed with muscle biopsy or genotype [+3]
Current investigational therapy that may affect cardiovascular function [+6]